Supporting Information

for

An improved synthesis of pyrido[2,3-*d*]pyrimidin-4(1*H*)ones and their antimicrobial activity

Mohamed Fares ^{a,b,*}, Soha R. Abd El Hadi ^b, Radwa A. Eladwy ^c, Aly A. Shoun ^d, Marwa M. Abdel-Aziz ^e, Wagdy M. Eldehna ^f, Hatem A. Abdel-Aziz ^g, Paul A. Keller ^{a,*}

^a School of Chemistry, University of Wollongong, Wollongong 2522, New South Wales, Australia
^bDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Egyptian Russian University, Badr City, Cairo, 11829, Egypt
^cDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Egyptian Russian University, Badr City, Cairo 11829, Egypt
^dDepartment of Microbiology & Immunology, Faculty of Pharmacy, Badr University in Cairo, Cairo, Egypt
^eThe Regional Center for Mycology and Biotechnology, Al-Azhar University, Cairo 11759, Egypt
^fDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt
^g Department of Applied Organic Chemistry, National Research Center, Dokki, Cairo 12622, Egypt


Table of Contents

General methods and material	SI3
General procedure for the preparation of propenones (3a-j)	SI3
General procedure A for the preparation of 10a-j	SI4
Procedure B for the preparation of 10a	SI4
Procedure C for the preparation of 10a	SI4
Typical procedure for the preparation of 11	SI8
Typical procedure for the preparation of 12	SI8
Pharmacokinetic properties calculation	SI9
Biological evaluation	SI9
In vitro cytotoxicity	SI10
References	SI10
NMR data of compounds 10a-j, 11 and 12	SI11

General methods and material

Melting points were measured with a Stuart apparatus and were uncorrected. Microwave reactions were carried out on a Discover SP - Microwave Synthesizer (CEM corporation, USA) with an emission frequency of 2455 MHz and 300 watts $\pm 10\%$. Reactions were monitored by TLC analysis using silica gel GF/UV 254. NMR spectra were recorded on Varian Gemini-300BB 300, 400 and 500 MHz FT-NMR spectrometers (Varian Inc., Palo Alto, CA) and Bruker 400 MHz FT-NMR spectrometer. ¹H spectra were run at 300, 400 and 500 MHz and ¹³C spectra were run at 100 and 125 MHz, in deuterated dimethylsulfoxide (DMSO- d_6). Chemical shifts ($\delta_{\rm H}$) are reported relative to TMS as internal standard and coupling constant (*J*) values are reported in Hertz. The abbreviations used are as follows: s, singlet; d, doublet; t, triplet; m, multiplet. Microanalyses were carried out using Perkin Elmer PE 2400 CHN Elemental Analyzer and the results were within \pm 0.4%. All reagents and solvents were purified and dried by standard techniques.


General procedure for the preparation of propenones (3a-j)¹



To a mixture of *p*-chloroacetophenone **1a** (154 mg, 1 mmole) or 2-acetyl thiophene **1b** (126 mg, 1 mmol) and the corresponding aldehyde **2a-e** (1 mmol) in methanol (5.0 mL), was slowly added a solution of potassium hydroxide

(5%, 1.2 mL). The mixture was stirred at room temperature for 12 h and the resulting precipitate filtered, washed with water, air dried, and recrystallized from ethanol. Yield: 62 - 75%; Melting points were consistent with that reported.¹

Synthesis of 2-Amino-2-thiouracil 6²




A sodium ethoxide solution was prepared by dissolving sodium (2.3 g, 0.1 mole) in absolute ethanol (150 mL). Thiourea **5** (3.8 g, 0.05 mole) was added with stirring until complete dissolution followed by the addition of ethyl cyanoacetate **4** (5.7 g, 0.05 mole) and the reaction mixture was heated at reflux

for 4 h. After cooling, water was added dropwise till complete dissolution of the white precipitate. Ice was added and neutralization of the alkaline solution was accomplished by adding HCl (5 M) dropwise. The reaction flask left overnight at 0 °C and the resulting white precipitate was filtered, washed with water (3 x 30 mL), diethyl ether (2 x 30 mL) then air dried to give **6** (4.86 g, 68%) as a white powder. m.p >300 °C as reported.²

General procedure A: Preparation of 5-aryl-7-(thiophen-2-yl / 4-chlorophenyl)-2-thioxo-2,3-dihydropyrido[2,3-*d*]pyrimidin-4(1*H*)-one 10a-j

A solution of 6-amino-2-thiouracil **6** (143 mg, 1 mmol) and the appropriate chalcone **3a-j** (1 mmol) in dry DMF (3 mL) was heated at reflux for 15-20 h and the reaction monitored by TLC analysis. The mixture was cooled overnight and the resulting solid filtered, dried and recrystallized from DMF to give the pyrido[2,3-*d*]pyrimidine derivatives **10a-j**.

7-(4-Chlorophenyl)-5-phenyl-2-thioxo-2,3-dihydropyrido[2,3-d]pyrimidin-4(1H)-one 10a³



Using general procedure A and 1-(4-chlorophenyl)-3-phenylprop-2-en-1-one **3a** (243 mg, 1 mmole), compound **10a** (161 mg, 44%) was isolated as a buff solid. M.p. >300 °C; ¹H NMR (DMSO- d_6) δ : 7.42-7.45 (m, 5H, ArH), 7.58 (d, 2H, J = 8.5 Hz, ArH), 7.66 (s, 1H, ArH), 8.26 (d, 2H, J = 8.5 Hz, ArH), 12.37 (s, 1H, NH); 13.08 (s, 1H, NH); ¹³C NMR (125 MHz, DMSO- d_6) δ : 108.2, 119.1, 127.4,

128.2, 128.7, 128.9, 129.4, 135.3, 135.7, 138.2, 152.6, 153.8, 157.9, 158.6, 175.4; MS (ESI⁻), *m/z* 364 (100%) [M-H]⁻, 380 (70%) [M + Cl]; Anal. Calcd for C₁₉H₁₂ClN₃OS: C, 62.38; H, 3.31; N, 11.49. Found: C, 62.56; H, 3.51; N, 11.26.

Procedure B: A solution of 6-amino-2-thiouracil **6** (143 mg, 1 mmol) and 1-(4-chlorophenyl)-3-phenylprop-2-en-1-one **3a** (242 mg, 1 mmol) in TFA (3 mL) was heated at reflux for 12 h and the reaction monitored by TLC analysis. The mixture was cooled, left overnight and the resulting solid filtered, washed with water (3 x 5 mL) then diethyl ether (2 x 5 mL) and dried to give **10a** (102 mg, 28%).

Procedure C: A solution of 6-amino-2-thiouracil **6** (72 mg, 0.5 mmol) and 1-(4-chlorophenyl)-3-phenylprop-2-en-1-one **3a** (121 mg, 0.5 mmol), iodine pellets (6.4 mg, 0.05 mmol) in dry DMF (2 mL) was subjected to microwave radiation in a sealed tube and the reaction monitored by TLC analysis. The mixture was cooled, the lid was removed, left overnight and the resulting solid filtered and dried (108 mg, 59%).




7-(4-Chlorophenyl)-5-(4-fluorophenyl)-2-thioxo-2,3dihydropyrido[2,3-*d*]pyrimidin-4(1*H*)-one 10b

Using general procedure A and 1-(4-chlorophenyl)-3-(4-fluorophenyl)prop-2-en-1-one **3b** (261 mg, 1 mmole), compound


10b (199 mg, 52%) was synthesized as a buff solid. M.p. >300 °C; ¹H NMR (DMSO- d_6) δ : 7.22 (t, 2H, J = 8.8 Hz ArH), 7.49 (dd, 2H, J = 6.0, 5.5 Hz, ArH), 7.58 (d, 2H, J = 8.8 Hz, ArH), 7.67 (s, 1H, pyridine H), 8.25 (d, 2H, J = 8.8 Hz, ArH), 12.38 (s, 1H, -NH, D₂O exchangeable); 13.08 (s, 1H, -NH, D₂O exchangeable); ¹³C NMR (125 MHz, DMSO- d_6) δ : 108.3, 114.2 (² J_{F-C} = 20.9 Hz), 119.1, 128.9, 129.3, 131.0 (³ J_{F-C} = 8.6 Hz), 134.4, 135.3, 135.8, 152.6, 152.7, 158.0, 158.7, 161.3 (¹ J_{F-C} = 243.1 Hz), 175.4; MS (ESI⁻), *m*/*z* 382 (100%) [³⁵Cl, M-H]⁻, 384 (33%) [³⁷Cl, M-H]⁻; Anal. Calcd for C₁₉H₁₁ClFN₃OS: C, 59.46; H, 2.89; N, 10.95. Found: C, 59.70; H, 3.11; N, 11.26.

5,7-Bis(4-chlorophenyl)-2-thioxo-2,3-dihydropyrido[2,3*d*]pyrimidin-4(1*H*)-one 10c



Using general procedure A and 1,3-bis(4-chlorophenyl)prop-2-en-1-one **3c** (277 mg, 1 mmole), compound **10c** (200 mg, 50%) was synthesized as a buff solid. M.p. >300 °C; ¹H NMR (DMSO- d_6) δ : 7.46-7.50 (m, 4H, ArH), 7.58 (d, 2H, J = 8.3 Hz, ArH), 7.68 (s, 1H, pyridine H), 8.25 (d, 2H, J = 8.3 Hz, ArH), 12.41 (s, 1H, -NH, D₂O

exchangeable), 13.10 (s, 1H, -NH, D₂O exchangeable); ¹³C NMR (125 MHz, DMSO-*d*₆) δ: 108.2, 118.9, 127.4, 128.9, 129.3, 130.6, 133.1, 135.2, 135.8, 137.1, 152.4, 152.6, 158.0, 158.7, 175.4; MS (ESI⁻), *m*/z 398 (100%) [³⁵Cl, ³⁵Cl, M-H]⁻, 400 (70%) [³⁷Cl, ³⁵Cl, M-H]⁻; Anal. Calcd for C₁₉H₁₁Cl₂N₃OS: C, 57.01; H, 2.77; N, 10.50. Found: C, 57.32; H, 2.85; N, 10.36.



7-(4-Chlorophenyl)-5-(4-methoxyphenyl)-2-thioxo-2,3dihydropyrido[2,3-*d*]pyrimidin-4(1*H*)-one 10d

Using general procedure A and 1-(4-chlorophenyl)-3-(4methoxyphenyl)prop-2-en-1-one **3d** (273 mg, 1 mmole), compound **10d** (181 mg, 46%) was synthesized as a buff solid. M.p. >300 °C; ¹H NMR (DMSO- d_6) δ : 3.81 (s, 3H, OCH₃), 6.94 (d, 2H, J = 8.0Hz, ArH), 7.39 (d, 2H, J = 8.0 Hz, ArH), 7.41 (d, 2H, J = 8.0 Hz,

ArH), 7.54 (s, 1H, pyridine H), 8.20 (d, 2H, J = 8.0 Hz, ArH), 12.37 (s, 1H, -NH, D₂O exchangeable), 12.02 (s, 1H, -NH, D₂O exchangeable); ¹³C NMR (100 MHz, DMSO- d_6) δ : 55.7, 108.6, 113.4, 119.6, 129.4, 129.8, 130.7, 131.0, 135.9, 136.1, 153.2, 154.1, 158.3, 159.2, 160.1, 175.8; MS (EI), m/z 395 (82%) [³⁵Cl, M]⁺, 397 (17%) [³⁷Cl, M]⁺; Anal. Calcd for C₂₀H₁₄ClN₃O₂S: C, 60.68; H, 3.56; N, 10.62. Found: C, 60.93; H, 3.78; N, 10.98.



7-(4-Chlorophenyl)-5-(4-nitrophenyl)-2-thioxo-2,3dihydropyrido[2,3-*d*]pyrimidin-4(1*H*)-one 10e

Using general procedure A and 1-(4-chlorophenyl)-3-(4nitrophenyl)prop-2-en-1-one **3e** (288 mg, 1 mmole), compound **10e** (250 mg, 61%) was synthesized as a buff solid. M.p. >300 °C; ¹H NMR (DMSO- d_6) δ : 7.62 (d, 2H, J = 8.8 Hz, ArH), 7.73 (d, 2H, J= 8.8 Hz, ArH), 7.76 (s, 1H, pyridine H), 8.27-8.35 (m, 4H, ArH),

12.48 (s, 1H, -NH, D₂O exchangeable), 13.19 (s, 1H, -NH, D₂O exchangeable); ¹³C NMR (100 MHz, DMSO-*d*₆) δ: 108.7, 119.0, 123.0, 129.5, 129.9, 130.6, 135.6, 136.4, 145.7, 147.7, 151.8, 153.0, 158.8, 159.2, 176.0; MS (EI), *m/z* 410 (100%) [³⁵Cl, M⁺], 412 (39%) [³⁷Cl, M]⁺.


5-Phenyl-7-(thiophen-2-yl)-2-thioxo-2,3-dihydropyrido[2,3-d]pyrimidin-4(1H)-one 10f⁴



Using general procedure A and 3-phenyl-1-(thiophen-2-yl)prop-2-en-1one **3f** (214 mg, 1 mmole), compound **10f** (219 mg, 65%) was synthesized as a buff solid. M.p. >300 °C; ¹H NMR (DMSO- d_6) δ : 7.18-7.19 (m, 1H, H4 thiophene), 7.38-7.52 (m, 5H, ArH), 7.59-7.70 (m, 1H, H5 thiophene), 7.92 (s, 1H, pyridine H), 8.07-8.15 (m, 1H, H3


thiophene), 12.29 (br. s, 1H, NH, D₂O exchangeable), 13.05 (br. s, 1H, NH, D₂O exchangeable); ¹³C NMR (100 MHz, DMSO- d_6) δ : 108.0, 118.1, 127.9, 128.6, 129.0, 129.4, 129.6, 132.5, 138.8, 142.8, 153.1, 154.0, 155.4, 158.9, 175.9; MS (EI), *m/z* 337 (100%) [M⁺], 338 (30%) [M+1]⁺; Anal. Calcd for C₁₇H₁₁N₃OS₂: C, 60.52; H, 3.29; N, 12.45. Found: C, 60.30; H, 3.26; N, 12.59.

5-(4-Fluorophenyl)-7-(thiophen-2-yl)-2-thioxo-2,3dihydropyrido[2,3-*d*]pyrimidin-4(1*H*)-one 10g



Using general procedure A and 3-(4-fluorophenyl)-1-(thiophen-2yl)prop-2-en-1-one **3g** (232 mg, 1 mmole), compound **10g** (202 MG, 57%) was synthesized as a buff solid. M.p. >300 °C; ¹H NMR (DMSO d_6) δ : 7.06-7.13 (m, 3H, 2ArH and H4 thiophene), 7.33 (t, 2H, J = 6.0 H, ArH), 7.46 (s, 1H, pyridine H), 7.68 (d, 1H, J = 4.0 Hz, H5 thiophene),

7.93 (d, 1H, J = 4.0 Hz, H3 thiophene), 12.22 (br. s, 1H, NH, D₂O exchangeable), 12.90 (br. s, 1H, NH, D₂O exchangeable); ¹³C NMR (100 MHz, DMSO-*d*₆) δ : 108.0, 114.7 (²*J*_{F-C} = 20.9 Hz), 118.1, 129.4, 129.7, 131.3 (³*J*_{F-C} = 9.0 Hz), 132.3, 135.0, 142.8, 152.9, 153.1, 155.5, 159.0, 161.5 (¹*J*_{F-C} = 240.0 Hz), 175.9; MS (EI), *m*/*z* 355 (100%) [M⁺], 356 (17%) [M+1]⁺; Anal. Calcd for C₁₇H₁₀FN₃OS₂: C, 57.45; H, 2.84; N, 11.82. Found: C, 57.64; H, 2.61; N, 12.09.



5-(4-Chlorophenyl)-7-(thiophen-2-yl)-2-thioxo-2,3-

dihydropyrido[2,3-*d*]pyrimidin-4(1*H*)-one 10h


Using general procedure A and 3-(4-chlorophenyl)-1-(thiophen-2yl)prop-2-en-1-one **3h** (249 mg, 1 mmole), compound **10h** (159 mg, 43%) was synthesized as a buff solid. M.p. >300 °C; ¹H NMR (DMSO d_6) δ : 7.20 (d, J = 3.9 Hz, 1H, H4 thiophene), 7.23 (d, J = 8.7 Hz, 2H, ArH), 7.45-7.59 (m, 3H, 2ArH and H5 thiophene), 7.81 (d, J = 4.8 Hz,

1H, H3 thiophene), 8.07 (s, 1H, pyridine H), 12.23 (br. s, 1H, NH, D₂O exchangeable), 12.95 (br s, 1H, NH, D₂O exchangeable); ¹³C NMR (100 MHz, DMSO-*d*₆) δ: 108.0, 117.9, 127.9, 129.4, 131.0, 132.4, 133.5, 137.6, 142.8, 152.6, 153.1, 155.5, 159.0, 162.1, 175.9; MS (EI), *m/z* 371 (100%) [³⁵Cl, M⁺], 373 (39) [³⁷Cl, M]⁺; Anal. Calcd for C₁₇H₁₀ClN₃OS₂: C, 54.91; H, 2.71; N, 11.30. Found: C, 54.72; H, 2.56; N, 11.56.

5-(4-Methoxyphenyl)-7-(thiophen-2-yl)-2-thioxo-2,3-dihydropyrido[2,3-d]pyrimidin-

4(1*H*)-one 10i


one 10j



Using general procedure A and 3-(4-methoxyphenyl)-1-(thiophen-2-yl)prop-2-en-1-one **3i** (244 mg, 1 mmole), compound **10i** (146 mg, 40%) was synthesized as a buff solid. M.p. >300 °C; ¹H NMR (DMSO- d_6) δ : 3.82 (s, 3H, OCH₃), 6.96 (d, J = 8.7 Hz, 2H, ArH), 7.20 (dd, J = 3.9, 4.8 Hz, 1H, H4 thiophene), 7.37 (d, J = 8.7 Hz, 2H, ArH), 7.56 (s, 1H,

pyridine H), 7.81 (d, J = 4.8 Hz, 1H, H5 thiophene), 8.06-8.08 (m, 1H, H3 thiophene), 12.23 (br. s, 1H, NH, D₂O exchangeable), 12.90 (br. s, 1H, NH, D₂O exchangeable); ¹³C NMR (100 MHz, DMSO- d_6) δ : 55.7, 107.9, 113.4, 118.1, 129.4, 129.5, 130.7, 130.8, 132.1, 142.9, 153.2, 153.8, 155.2, 159.0, 160.0, 175.8; MS (EI), *m/z* 367 (100%) [M⁺]; Anal. Calcd for C₁₈H₁₃N₃O₂S₂: C, 58.84; H, 3.57; N, 11.44. Found: C, 59.02; H, 3.74; N, 11.30.

$\label{eq:constraint} 5-(4-Nitrophenyl)-7-(thiophen-2-yl)-2-thioxo-2, \\ 3-dihydropyrido[2, 3-d]pyrimidin-4(1H)-2-yl)-2-thioxo-2, \\ 3-dihydropyrido[2, 3-d]pyrimidin-4(1H)-2-thioxo-2, \\ 3-dihydropyrimidin-4(1H)-2-thioxo-2, \\ 3-dihydropyrimidin-4(1H)-2-thioxo-2, \\ 3-dihydropyrimidin-4(1H)-2-thioxo-2, \\ 3-dihydropyrimidin-4(1H)-2-thioxo-2, \\ 3-dihydropyrimidin-4(1H)-2-thioxo-2,$




Using general procedure A and 3-(4-nitrophenyl)-1-(thiophen-2yl)prop-2-en-1-one **3j** (259 mg, 1 mmole), compound **10j** (191 mg, 50%) was synthesized as a buff solid. M.p. >300 °C; ¹H NMR (DMSO d_6) δ : 7.21 (dd, J = 3.9, 1.2 Hz, 1H, H4 thiophene), 7.66-7.67 (m, 1H, H5 thiophene), 7.68 (d, J = 8.7 Hz, 2H, ArH), 7.83 (d, J = 5.1 Hz, 1H,

H3 thiophene), 8.07 (s, 1H, pyridine H), 8.26 (d, J = 8.7 Hz, 2H, ArH), 12.34 (br. s, 1H, NH, D₂O exchangeable), 13.05 (br. s, 1H, NH, D₂O exchangeable); ¹³C NMR (100 MHz, DMSO-*d*₆)

δ: 107.9, 117.5, 123.0, 124.4, 126.4, 129.5, 130.4, 130.5, 132.6, 147.7, 151.5, 153.0, 155.8, 159.1, 176.0; MS (EI), *m/z* 382 (100%) [M⁺], 383 (37%) [M+1]⁺; Anal. Calcd for C₁₈H₁₃N₃O₂S₂: C, 58.84; H, 3.57; N, 11.44. Found: C, 58.98; H, 3.86; N, 11.62.


7-(4-Chlorophenyl)-2-(dimethylamino)-5-phenylpyrido[2,3-d]pyrimidin-4(3H)-one 11



A solution of 6-amino-2-thiouracil 6 (72 mg, 0.5 mmol), 1-(4chlorophenyl)-3-phenylprop-2-en-1-one **3a** (121 mg, 0.5 mmol) and iodine (25 mg, 40 mol%) in dry DMF (2 mL) was subjected to microwave radiation for 1 h in a sealed tube and the reaction monitored by TLC analysis. The mixture was

cooled, the lid was removed, left overnight and the resulting solid was subjected to flash chromatography (methanol/dichloromethane, 1:10) to give **11** (73 mg, 39%) as a yellow powder, M.p. >300 °C; ¹H NMR (DMSO, d_6) δ : 3.14 (s, 6H, 2CH₃), 7.39-7.45 (m, 6H, 5ArH and pyridine H), 7.54 (d, J = 8.3 Hz, 2H, ArH), 8.22 (d, J = 8.3 Hz, 2H, ArH), 11.20 (s, 1H, NH); ¹³C NMR (125 MHz, DMSO- d_6) δ : 38.0, 107.7, 117.5, 126.0, 127.8, 128.2, 129.0, 129.2, 129.7, 135.5, 137.0, 140.2, 153.6, 153.8, 158.7, 163.1; MS (ESI⁺), *m/z* 377 (100%) [³⁵Cl, M+H]⁺, 379 32% [³⁷Cl, M+H]; HRMS (ESI⁺) calcd for C₂₁H₁₇ClN₄O+H: 377.1187; found 377.1169.

2-Amino-7-(4-chlorophenyl)-5-phenylpyrido[2,3-d]pyrimidin-4(3H)-one 12



A solution of 6-amino-2-thiouracil **6** (72 mg, 0.5 mmol), 1-(4chlorophenyl)-3-phenylprop-2-en-1-one **3a** (121 mg, 0.5 mmol) and iodine (25 mg, 40 mol%) in formamide (2 mL) was subjected to microwave radiation for 1 h in a sealed tube and the reaction monitored by TLC analysis. The mixture was cooled, the lid was

removed, left overnight and the resulting solid was subjected to flash chromatography (methanol/dichloromethane, 1:10) to give **12** (60 mg, 34%) as a brown powder. M.p. >300 °C; ¹H NMR (DMSO-*d*₆) δ : 6.69 (s, 2H, NH₂), 7.39-7.54 (m, 6H, 5ArH and pyridine H), 7.54 (d, *J* = 8.3 Hz, 2H, ArH), 8.21 (d, *J* = 8.3 Hz, 2H, ArH), 10.95 (s, 1H, NH); ¹³C NMR (125 MHz, DMSO-*d*₆) δ : 108.5, 117.3, 127.7, 128.0, 129.0, 129.2, 129.5, 135.4, 137.1, 140.4, 153.7, 154.7, 158.4, 163.4, 163.5; MS (ESI⁺), *m/z* 349 (100%) [³⁵Cl, M+H]⁺, 351 (35%) [³⁷Cl, M+H]⁺; HRMS (ESI⁺) calcd for C₁₉H₁₃ ³⁵ClN₄O + Na: 371.0669; found 371.0676.

Pharmacokinetic properties calculation

The drug likeness, HBD and HBA scores of all the compounds **10a-j** were calculated using the MolSoft online calculation kits. Prediction of the lipophilicity was performed using ALOGPS

2.1 program ⁵, while calculation of TPSA, the number of rotatable bonds, used the Molinspiration property calculation kit.⁶ Reduced molecular flexibility is measured by the number of rotatable bonds and is greatly linked to oral bioavailability. The number of rotatable bonds less or equal to ten potentially increases the oral bioavailability. %ABS is inversely proportional to the molecular volume and TPSA and is calculated using the formula %ABS = $109 \pm 0.345 \times TPSA$.

Biological evaluation

Antimicrobial activity

All strains were provided by the Regional Center for Mycology and Biotechnology (RCMB), Al-Azhar University, Cairo, Egypt. Antibacterial and antifungal activities were expressed as the diameter of inhibition zones from an agar well diffusion method. Holes (1 cm diameter) were created in the agar using a sterile cork borer in either sterile malt agar plates (fungi) or sterile nutrient agar plates (bacteria), which had previously been uniformly seeded with microorganisms. The holes were filled with fungal filtrates (100 μ L). Plates were left in an incubator at 4 °C for one hour for diffusion and then incubated at 37 °C for bacteria and 28 °C for fungi. Inhibition zones were measured after 24 h of incubation for bacteria and 48 h of incubation for fungi. Amphotericin B was the antifungal standard, whereas ampicillin, gentamycin and vancomycin served as standards for Gram +ve, Gram -ve, and methicillin resistant *Staphylococcus aureus*, respectively. The experiments were performed in triplicate and the average zone of inhibition was calculated.

Minimum inhibitory concentration

MIC was performed using a serial dilution technique starting with 100 mmol concentration of compounds dissolved in DMSO (1 mL) and then reduced by successive twofold dilutions of stock solution using a calibrated micropipette. Amphotericin B was used as the antifungal standard and ampicillin, gentamycin and vancomycin served as standards for Gram +ve, Gram -ve, and methicillin resistant *Staphylococcus aureus*, respectively. The final solution concentrations were 62.50, 31.25, 15.63, 7.81, 3.90, 1.95, 0.98, 0.49, 0.24 and 0.12 µmol/mL. The microtiter plates were incubated at 37 °C for bacteria and 28 °C for fungi and were read using a microplate reader after 24 h for bacteria and after 48 h for fungi. In each case, triplicate tests were performed and the average was taken as final reading. MIC was expressed as the lowest concentration inhibiting test organism's growth.


In vitro cytotoxicity

CCD-33Co (normal colon cells) were obtained from the American Type Culture Collection. Cells were propagated in DMEM supplemented with 10% heat-inactivated FBS (Hyclone), 10 μ g/mL

of insulin (Sigma), and 1% penicillin-streptomycin. All other chemicals and reagents were purchased from Sigma, or Invitrogen. Cytotoxicity was determined using a MTT assay following a reported procedure.⁷ The 50% inhibitory concentration (IC_{50}) was estimated from graphic plots of the dose response curve for each conc. using Graphpad Prism software (San Diego, CA. USA). The data presented are the mean of three separate experiments.

References:

- 1. Y. Qian, G.-Y. Ma, Y. Yang, K. Cheng, Q.-Z. Zheng, W.-J. Mao, L. Shi, J. Zhao and H.-L. Zhu, *Biorg. Med. Chem.*, 2010, **18**, 4310-4316.
- 2. T. Elsaman, M. Fares, H. A. Abdel-Aziz, M. I. Attia, H. A. Ghabbour and K. M. Dawood, *J. Chem.*, 2013, **2013**.
- 3. J. Quiroga, B. Insuasty, A. Sanchez, M. Nogueras and H. Meier, *J. Heterocycl. Chem.*, 1992, **29**, 1045-1048.
- 4. M. Fares, S. M. Abou-Seri, H. A. Abdel-Aziz, S. E. Abbas, M. M. Youssef and R. A. Eladwy, *Eur. J. Med. Chem.*, 2014, **83**, 155-166.
- 5. I. V. Tetko and V. Y. Tachuk, http://www.vcclab.org/lab/alogps/.
- 6. M. Cheminformatics, http://www.molinspiration.com/cgi-bin/properties.
- 7. F. Denizot and R. Lang, J. Immunol. Methods, 1986, 89, 271-277.




mm160728_H_4_C1_Acetophenone_PP_CARBON

Sample Name: mm160728_H_4_C1_Acetophenone PP Data Collected on: ernst.sci.uow.edu.au-inova500 Archive directory:

Sample directory:

FidFile: CARBON





O

N H

NΗ

Agilent Technologies







File: Proton


Pulse Sequence: s2pul

Solvent: dmso Temp. 25.0 C / 298.1 K Operator: uowvnmrs VNMRS-500 "pyne06.domain.com"

Relax. delay 0.001 sec Pulse 45.0 degrees Acq. time 2.045 sec Width 8012.8 Hz Single scan OBSERVE H1, 499.7437645 MHz DATA PROCESSING Line broadening 0.5 Hz FT size 65536 Total time 0 min, 2 sec







13	12	11	10	9	8	7	6	5	4	3	2	1	ppm


mm160726_4_C1_Benzald_4_C1_Acetophenone_Carbon


File: Carbon

Pulse Sequence: s2pul

Solvent: dmso Temp. 25.0 C / 298.1 K Operator: uowvnmrs VNMRS-500 "pyne06.domain.com"


Relax. delay 0.500 sec Pulse 45.0 degrees Acq. time 1.500 sec Width 30487.8 Hz 1280 repetitions OBSERVE C13, 125.6607298 MHz DECOUPLE H1, 499.7462675 MHz Power 45 dB continuously on WALTZ-16 modulated DATA PROCESSING Line broadening 1.0 Hz FT size 65536 Total time 59 min, 59 sec







635


30.




WAGDY(5)-13C-DMSO-272017














	Current I NAME EXPNO PROCNO	Data Parameters Jul02-2017-nmr 6 1	
	F2 - Acqu Date_ Time INSTRUM PROBHD PULPROG TD SOLVENT NS DS SWH FIDRES AQ RG DW DE TE D1 D11 TD0	uisition Paramet 20170702 22.44 spect 5 mm PABBO BB/ 2gpg30 65536 DMSO 1024 4 24038.461 0.366798 1.3631488 194.81 20.800 6.50 300.0 2.0000000 0.03000000	Hz Hz sec usec usec K sec
	======= SFO1 NUC1 P1 PLW1	CHANNEL f1 ==== 100.6328883 13C 10.00 66.00000000	MHz usec
	SF02 NUC2 CPDPRG[2 PCPD2 PLW2 PLW12 PLW13	CHANNEL f2 ==== 400.1716007 1H waltz16 90.00 16.5000000 0.20370001 0.16500001	MHz usec W W
Valendeproprieterietungenen andere er einer andere andere andere andere andere andere andere andere andere ande	F2 - Prod SI SF WDW SSB LB	cessing paramete 32768 100.6228270 EM 0 1.00	MHz
0 30 20 ppm	GB PC	0 1.40	





190 180 170 160 150 140 130 120 110 100 90




.....









Dr.MohamedFars-8PP-H1-DMS0-Main.Defence.Chemical.Laboratory


Pulse Sequence: s2pul

-

1 2

Solvent: DMSO Temp. 25.0 C / 298.1 K GEMINI-300BB "NMR"

Relax. delay 1.000 sec Pulse 45.0 degrees Acq. time 3.127 sec Width 6000.2 Hz 20 repetitions OBSERVE H1, 300.0117460 MHz DATA PROCESSING FT size 65536 Total time 5 min, 5 sec





CI 0 ΝH Ĥ 10h

O NH	BŔ	ÚKÉR
N N S H	Current I NAME EXPNO PROCNO	Data Parameters Jul02-2017-nmr 8 1
	F2 - Acqu Date_ Time INSTRUM PROBHD PULPROG TD SOLVENT NS DS SWH FIDRES AQ RG DW DE TE D1 D11 TD0	aisition Parameters 20170703 0.49 spect 5 mm PABBO BB/ 2gpg30 65536 DMSO 1024 4 24038.461 Hz 0.366798 Hz 1.3631488 sec 194.81 20.800 usec 6.50 usec 300.0 K 2.00000000 sec 0.03000000 sec 1
	SF01 NUC1 P1 PLW1	CHANNEL f1 ====== 100.6328883 MHz 13C 10.00 usec 66.0000000 W
	SF02 NUC2 CPDPRG[2 PCPD2 PLW2 PLW12 PLW13	CHANNEL f2 ====== 400.1716007 MHz 1H waltz16 90.00 usec 16.5000000 W 0.20370001 W 0.16500001 W

F2 - Processing parameters SI 32768 SF 100.6228270 MHz WDW EM

1.00 Hz

1.40


0

0

SSB LB

GB

PC



175.87	162.10 159.02 155.53 155.53 153.08 152.55	L 10 10 m 0 L m 0 0	107.95

140

120

100

80

60


40

20

0

ppm





Dr.MohamedFars-9PP-H1-DMSO-Main.Defence.Chemical.Laboratory


Pulse Sequence: s2pul


·9 ·*

2

Solvent: DMSO Temp. 25.0 C / 298.1 K File: Dr.MohamedFars-9PP-H1-DMSO-Main.Defence.Chemical.Laboratory GEMINI-300BB "NMR"

Relax. delay 1.000 sec Pulse 45.0 degrees Acq. time 3.127 sec Width 6000.2 Hz 20 repetitions OBSERVE H1, 300.0117460 MHz DATA PROCESSING FT size 65536 Total time 5 min, 5 sec








.822

3

	- 175.76	<pre>160.01 160.01 155.24 153.22 153.22</pre>	00 H L	 130.72 129.46 129.35 118.11 113.37 107.89 		55.68	40.63 40.43 40.22 39.59 39.38		C	\sim
				NF		H [°] S			Current Da NAME C EXPNO PROCNO F2 - Acqui Date_ Time INSTRUM	Ata Parameters Julo2-2017-nmr 9 1 isition Parameters 20170703 1.51 spect 5 mm PABBO BB/ zgpg30 65536 DMSO 1024 4 24038.461 Hz
									FIDRES AQ RG DW DE TE D1 D11 TD0 ======= C SF01 NUC1 P1 PLW1	24038.461 H2 0.366798 Hz 1.3631488 sec 194.81 20.800 usec 6.50 usec 300.0 K 2.00000000 sec 0.03000000 sec 1 CHANNEL f1 ======= 100.6328883 MHz 13C 10.00 usec 66.00000000 W CHANNEL f2 ======
									SF02 NUC2 CPDPRG[2 PCPD2 PLW2 PLW12 PLW13 F2 - Proce SI SF WDW SSB (LB	400.1716007 MHz 1H waltz16 90.00 usec 16.5000000 W 0.20370001 W 0.16500001 W essing parameters 32768 100.6228270 MHz EM 1.00 Hz
1 200 1	1 80	1 160	140	120	100 80	1 60		20 ppm	GB C PC	1.40







n

8.283 224 662



